Cancerostatische Proteinkomponenten ausViscum album

Vester, F.; Nienhaus, Jürgen

doi:10.1007/bf02141882

Cited by 9 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mistletoe extract was first introduced for cancer treatment by Rudolf Steiner [ 29 ]. Cancerostatic protein components from Viscum album were later identified as cytotoxic viscotoxins and mistletoe lectins [ 30 ]. Mistletoe extract induces apoptosis and cytotoxicity in cancer cells [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study

et al. 2021

View full text Add to dashboard Cite

Background Mistletoe extract, used as a complementary chemotherapeutic agent for cancer patients, has anticancer effects against various malignancies. The aim of the present study was to evaluate the effect of mistletoe extract (Abnoba Viscum Q®) on tumor responses to neoadjuvant chemoradiotherapy (NCRT) for locally advanced rectal cancer. Methods This study included patients with rectal cancer who underwent NCRT between January 2018 and July 2020. In the mistletoe group (MG), the patients were administered Abnoba Viscum Q® subcutaneously during chemoradiotherapy—maintained just before surgery. Patient demographics, clinical outcomes, histopathological outcomes, and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) assay results were compared between the MG and non-mistletoe group (NMG). Two rectal cancer cell lines (SNU-503 and SNU-503R80Gy) were treated with Abnoba Viscum Q® to assess its mechanistic effects in vivo. Results Overall, the study included 52 patients (MG: n = 15; NMG: n = 37). Baseline demographics between the two groups were similar, except carbohydrate antigen 19-9 levels and tumor location from the anal verge. There was no difference in the clinical stage between the two groups. A better tumor response in the MG, relative to the NMG, was observed with respect to tumor regression grade (TRG), T stage, and overall tumor–node–metastasis stage. Tumor response was significantly better in the MG than in the NMG in terms of pathologic complete response rate (53.3% vs. 21.6%, P = 0.044), good TRG response (66.7% vs. 32.4%, P = 0.024), T downstaging (86.7% vs. 43.2%, P = 0.004), and overall downstaging (86.7% vs. 56.8%, P = 0.040). The toxicities during NCRT were minimal in both groups. More apoptotic cells were noted in MG samples than in the NMG samples on TUNEL staining. Cleaved caspase-3 level following treatment with Abnoba Viscum Q® was higher in SNU-503R80Gy cells than in SNU-503 cells. Conclusion Patients treated with chemoradiation combined with mistletoe extract showed better outcomes than patients not treated with mistletoe extract in terms of tumor responses. This diversity in treatment may improve the efficacy of NCRT, leading to better oncologic outcomes. Prospective and randomized studies with long-term follow-up are warranted to confirm and extend these results.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…During the 1960s, Vester and Nienhaus isolated carcinostatic protein fractions which were recognized later as the cytotoxic viscotoxins and mistletoe lectins [6]. Recent scientific research has confirmed the folklore with evidence that mistletoe extracts (1) induce apoptosis, (2) stimulate immunocompetent cells, and (3) protect the DNA of mononuclear cells (for review see [7,8]).…”

Section: Introductionmentioning

confidence: 99%

Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review

2009

View full text Add to dashboard Cite

BackgroundIn Europe, extracts from Viscum album (VA-E), the European white-berry mistletoe, are widely used to treat patients with cancer.MethodsWe searched several databases such as Cochrane, EMBASE, NCCAM, NLM, DIMDI, CAMbase, and Medline. Inclusion criteria were controlled clinical studies on parameters associated with survival in cancer patients treated with Iscador. Outcome data were extracted as they were given in the publication, and expressed as hazard ratios (HR), their logarithm, and the respective standard errors using standard formulas.ResultsWe found 49 publications on the clinical effects of Iscador usage on survival of cancer patients which met our criteria. Among them, 41 studies and strata provided enough data to extract hazard ratios (HR) and their standard errors (Iscador versus no extra treatment). The majority of studies reported positive effects in favour of the Iscador application. Heterogeneity of study results was moderate (I2 = 38.3%, p < 0.0001). The funnel plots were considerably skewed, indicating a publication bias, a notion which is corroborated by statistical means (AC = -1.3, CI: -1.9 to -0.6, p <= 0.0001). A random effect meta-analysis estimated the overall hazard ratio at HR = 0.59 (CI: 0.53 to 0.66, p < 0.0001). Randomized studies showed less effects than non-randomized studies (ratio of HRs: 1.24, CI: 0.79 to 1.92, p = 0.35), and matched-pair studies gave significantly better results than others (ratio of HRs: 0.33; CI: 0.17 to 0.65, p = 0.0012).ConclusionsPooled analysis of clinical studies suggests that adjuvant treatment of cancer patients with the mistletoe extract Iscador is associated with a better survival. Despite obvious limitations, and strong hints for a publication bias which limits the evidence found in this meta-analysis, one can not ignore the fact that studies with positive effects of VA-E on survival of cancer patients are accumulating. Future studies evaluating the effects of Iscador should focus on a transparent design and description of endpoints in order to provide greater insight into a treatment often being depreciated as ineffective, but highly valued by cancer patients.

show abstract

“…4], Recently, a number of controlled clinical trials have been started and there are sugges tions that Iscador may be beneficial in the post operative treatment of lung, breast, colon, and cervi cal carcinomas [2, 5 7]. The anticancer activities of mistletoe have been ascribed to a combination of cytotoxic [8 18] and immunological effects [18][19][20][21], and mistletoe treatments, unlike cytotoxic drugs, arc not immunosuppressive [2], In this paper we would like to review methods used for in vitro and in vivo evaluation of anticancer agents with special reference to work on mistletoe extracts and its alkaloidal com ponents. The possible contributions of mistletoe alka loids towards a mechanism of the anticancer activity of the extract will be discussed.…”

Section: Introductionmentioning

confidence: 99%

Recent Studies on the Anticancer Activities of Mistletoe <i>(Viscum album) </i>and Its Alkaloids

Khwaja

Dias

Pentecost³

1986

Oncology

View full text Add to dashboard Cite

Detailed methods for in vitro/in vivo evaluation of anticancer drugs, with special reference to mistletoe extracts, have been reviewed. Mistletoe extracts have been shown to possess significant antitumor activity, in vivo, against murine tumors, Lewis lung carcinoma, colon adenocarcinoma 38 and C3H mammary adenocarcinoma 16/C. Methods for the extraction of biologically active alkaloids from mistletoe and their anticancer activities are presented. The possible origin of alkaloids in mistletoe plants, and their contributions towards a mechanism of anticancer activities of mistletoe axtracts, are proposed.

show abstract

Cancerostatische Proteinkomponenten ausViscum album

Cited by 9 publications

References 4 publications

Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study

Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study

Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review

Recent Studies on the Anticancer Activities of Mistletoe <i>(Viscum album) </i>and Its Alkaloids

Contact Info

Product

Resources

About